Changes in Hong Kong stocks | Changfeng Pharmaceutical (02652) surged more than 10% in early trading ICF001 clinical licenses for multiple indications, and the company will speed up phase I clinical research at home and abroad

The Zhitong Finance App learned that Changfeng Pharmaceutical (02652) surged more than 10% in early trading. As of press release, it had risen 8.23% to HK$10.39, with a turnover of HK$287.44,300.

According to news, recently, the innovative drug candidate ICF001, an innovative drug developed independently by Changfeng Pharmaceutical, has obtained implied approval for three consecutive clinical trials. So far, the innovative drug has achieved full coverage of the four major indications of PAH, PH-ILD, IPF, and PPF, making it the first domestic enterprise to advance this type of long-term inhalation precursor drug to the clinical trial stage in China. Chairman and Executive Director Dr. Liang Wenqing said that phase I clinical research at home and abroad will be promoted simultaneously, and global paths such as overseas cooperative development and regional licensing will be actively explored.

It is worth mentioning that at the 2026 Xiamen Science and Technology Innovation Industry and Securities Industry Development Conference and Securities Industry Golden Bull Award Conference held on September 6, the company won the “2026 Golden Bull Award for Science and Technology Innovation”. This award is an authoritative science and innovation award with great credibility in the domestic capital market. This award confirms the company's innovative development strength to deeply cultivate the high-end pharmaceutical circuit and adhere to a global strategy.